-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Annonce événementielle au sens de l’art. 53 RCExercice entierReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineOncologyMedical InnovationsCancerAd Hoc
-
Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-…Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint1. Topline results showed a significant proportion of patients treated with iptacopan (200 mg twice daily…Reimagine MedicineMedical InnovationsInnovation
-
Basel, December 13, 2022 — Novartis today announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy. Pluvicto® is approved in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult…Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, December 13, 2022 — Novartis today announced detailed results from the pivotal Phase III APPLY-PNH trial1. The results showed a vast majority of patients with paroxysmal nocturnal hemoglobinuria (PNH) who received the investigational oral monotherapy iptacopan achieved clinically meaningful increases in hemoglobin levels compared to anti-C5…Reimagine MedicineMedical InnovationsInnovation
-
Annonce événementielle au sens de l’art. 53 RC
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Annonce événementielle au sens de l’art. 53 RC
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Ad-hoc-Mitteilung gemäss Art. 53 KR
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Ad-hoc-Mitteilung gemäss Art. 53 KR
Reimagine MedicineAd HocAccess to Healthcare